Your browser doesn't support javascript.
loading
Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification.
Ursenbach, Axel; Ruch, Yvon; Hoellinger, Baptiste; Fuchs, Anne; Caspar, Stéphanie; Jegou, Frédérick; Rey, David; Fafi-Kremer, Samira; Mesplède, Thibault; Gantner, Pierre.
Affiliation
  • Ursenbach A; Le Trait d'Union, HIV-Infection Care Center, Strasbourg University Hospital, Strasbourg, France.
  • Ruch Y; Infectious Diseases Department, Strasbourg University Hospital, Strasbourg, France.
  • Hoellinger B; Infectious Diseases Department, Strasbourg University Hospital, Strasbourg, France.
  • Fuchs A; Clinical Virology Laboratory, Strasbourg University Hospital, Strasbourg, France.
  • Caspar S; Clinical Virology Laboratory, Strasbourg University Hospital, Strasbourg, France.
  • Jegou F; Clinical Virology Laboratory, Strasbourg University Hospital, Strasbourg, France.
  • Rey D; Le Trait d'Union, HIV-Infection Care Center, Strasbourg University Hospital, Strasbourg, France.
  • Fafi-Kremer S; Clinical Virology Laboratory, Strasbourg University Hospital, Strasbourg, France.
  • Mesplède T; INSERM UMR_S1109, Strasbourg University, Strasbourg, France.
  • Gantner P; Viroscience Department, Erasmus Medical Center, Rotterdam, The Netherlands.
Clin Infect Dis ; 79(1): 198-201, 2024 Jul 19.
Article in En | MEDLINE | ID: mdl-38193816
ABSTRACT
Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Oxazines / Piperazines / Pyridones / HIV Infections / Lamivudine / Anti-HIV Agents / Drug Resistance, Viral / Heterocyclic Compounds, 3-Ring Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Oxazines / Piperazines / Pyridones / HIV Infections / Lamivudine / Anti-HIV Agents / Drug Resistance, Viral / Heterocyclic Compounds, 3-Ring Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2024 Type: Article